GeneReach Biotechnology Balance Sheet Health
Financial Health criteria checks 4/6
GeneReach Biotechnology has a total shareholder equity of NT$862.4M and total debt of NT$139.6M, which brings its debt-to-equity ratio to 16.2%. Its total assets and total liabilities are NT$1.2B and NT$313.7M respectively.
Key information
16.2%
Debt to equity ratio
NT$139.62m
Debt
| Interest coverage ratio | n/a |
| Cash | NT$502.72m |
| Equity | NT$862.44m |
| Total liabilities | NT$313.71m |
| Total assets | NT$1.18b |
Recent financial health updates
Recent updates
Does GeneReach Biotechnology (GTSM:4171) Have A Healthy Balance Sheet?
Apr 18
Will Weakness in GeneReach Biotechnology Corp.'s (GTSM:4171) Stock Prove Temporary Given Strong Fundamentals?
Feb 28We Like GeneReach Biotechnology's (GTSM:4171) Returns And Here's How They're Trending
Jan 31The GeneReach Biotechnology (GTSM:4171) Share Price Is Up 596% And Shareholders Are Delighted
Dec 27
GeneReach Biotechnology Corp.'s (GTSM:4171) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Nov 28Financial Position Analysis
Short Term Liabilities: 4171's short term assets (NT$632.1M) exceed its short term liabilities (NT$205.9M).
Long Term Liabilities: 4171's short term assets (NT$632.1M) exceed its long term liabilities (NT$107.8M).
Debt to Equity History and Analysis
Debt Level: 4171 has more cash than its total debt.
Reducing Debt: 4171's debt to equity ratio has reduced from 101.2% to 16.2% over the past 5 years.
Debt Coverage: 4171's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if 4171's interest payments on its debt are well covered by EBIT.